

PFIZER
UNASYN
(Sulbactam Sodium/Ampicillin Sodium)
For Intravenous or Intramuscular Use

1. NAME OF THE MEDICINAL PRODUCT

UNASYN IM/IV

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Sulbactam sodium is a derivative of the basic penicillin nucleus. Chemically it is sodium penicillanate sulfone and is an off-white crystalline powder highly soluble in water. The molecular weight is 255.22.

Ampicillin sodium is derived from the penicillin nucleus, 6-aminopenicillanic acid. Chemically, it is D(-)- α -aminobenzyl penicillin sodium salt and has a molecular weight of 371.39.

Sulbactam sodium/ampicillin sodium IM/IV contains sulbactam sodium and ampicillin sodium in a 1:2 ratio.

3. PHARMACEUTICAL FORM

Sulbactam sodium/ampicillin sodium IM/IV combination is available as a dry powder for reconstitution in vials containing the equivalent of 1,000 mg + 2,000 mg, 500 mg + 1,000 mg, 250 mg + 500 mg of sulbactam and ampicillin, respectively.

4. CLINICAL PARTICULARS

4.1 Therapeutic Indications

Sulbactam sodium/ampicillin sodium IM/IV is indicated for infections caused by susceptible microorganisms. Typical indications are upper and lower respiratory tract infections including sinusitis, otitis media and epiglottitis; bacterial pneumonias; urinary tract infections and pyelonephritis; intra-abdominal infections including peritonitis, cholecystitis, endometritis and pelvic cellulitis; bacterial septicemia; skin, soft tissue, bone and joint infections and gonococcal infections.

Sulbactam sodium/ampicillin sodium IM/IV may also be administered peri-operatively to reduce the incidence of post-operative wound infections in patients undergoing abdominal or pelvic surgery, in which peritoneal contamination may be present. In termination of pregnancy or cesarean section, sulbactam sodium/ampicillin sodium IM/IV may be used prophylactically to reduce post-operative sepsis.

4.2 Posology and Method of Administration

Sulbactam sodium/ampicillin sodium IM/IV can be administered by either intravenous or intramuscular routes. The following dilutions may be used:

Total Dosage (g)	Equivalent Dosage of Sulbactam-Ampicillin (g)	Package	Diluent Volume (ml)	Maximum Final Concentration (mg/ml)
0.75	0.25-0.5	10 ml vial	1.6	125-250
1.5	0.5-1.0	20 ml vial	3.2	125-250
3.0	1.0-2.0	20 ml vial	6.4	125-250

For intravenous administration, sulbactam sodium/ampicillin sodium IM/IV should be reconstituted with sterile water for injection or any compatible solution (see section 6.6 - **Special Precautions for Disposal and Other Handling**). To ensure complete dissolution, allow foaming to dissipate in order to visually inspect. The dose can be given by bolus injection over a minimum of 3 minutes or can be used in greater dilutions as an intravenous infusion over 15-30 minutes.

Sulbactam sodium/ampicillin sodium parenteral may also be administered by deep intramuscular injection; if pain is experienced, 0.5% sterile solution for injection of lignocaine hydrochloride anhydrous may be used for reconstitution of the powder.

Use in Adults

The usual dosage range of sulbactam sodium/ampicillin sodium IM/IV is 1.5 g to 12 g per day in divided doses every 6 or 8 hours up to a maximum daily dosage of sulbactam of 4 g. Less severe infections may be treated on an every-12-hours schedule.

SEVERITY OF INFECTION	DAILY DOSE OF SULBACTAM SODIUM/AMPICILLIN SODIUM IM/IV (g)
Mild	1.5 to 3 (0.5 + 1 to 1 + 2)
Moderate	up to 6 (2 + 4)
Severe	up to 12 (4 + 8)

More or less frequent dosing may be indicated depending on the severity of the illness and the renal function of the patient. Treatment is usually continued until 48 hours after pyrexia and other abnormal signs have resolved. Treatment is normally given for 5 to 14 days, but the treatment period may be extended or additional ampicillin may be administered in severely ill cases.

In treating patients on restricted sodium intake, it should be noted that 1,500 mg of sulbactam sodium/ampicillin sodium IM/IV contains approximately 115 mg (5 mmol) of sodium.

For the prophylaxis of surgical infections, 1.5-3 g of sulbactam sodium/ampicillin sodium IM/IV should be given at induction of anesthesia, which allows sufficient time to achieve effective serum and tissue concentrations during the procedure. The dose may be repeated every 6-8 hours; administration is usually stopped 24 hours after the majority of surgical procedures, unless a therapeutic course of sulbactam sodium/ampicillin sodium IM/IV is indicated.

In the treatment of uncomplicated gonorrhea, sulbactam sodium/ampicillin sodium IM/IV can be given as a single dose of 1.5 g. Concomitant probenecid 1.0 g orally should be administered in order to prolong plasma concentrations of sulbactam and ampicillin.

Use in Children, Infants and Neonates

The dosage of sulbactam sodium/ampicillin sodium IM/IV for most infections in children, infants and neonates is 150 mg/kg/day (corresponding to sulbactam 50 mg/kg/day and ampicillin 100 mg/kg/day).

In children, infants and neonates, dosing is usually every 6 or 8 hours in accordance with the usual practice for ampicillin.

In neonates during the first week of life (especially preterms), the recommended dose is 75 mg/kg/day (corresponding to 25 mg/kg/day sulbactam and 50 mg/kg/day ampicillin) in divided doses every 12 hours.

Use in Patients with Renal Impairment

In patients with severe impairment of renal function (creatinine clearance ≤ 30 ml/min), the elimination kinetics of sulbactam and ampicillin are similarly affected and hence the plasma ratio of one to the other will remain constant. The dose of sulbactam sodium/ampicillin sodium IM/IV in such patients should be administered less frequently in accordance with the usual practice for ampicillin.

4.3 Contraindications

The use of this combination is contraindicated in individuals with a history of an allergic reaction to any of the penicillins.

4.4 Special Warnings and Precautions for Use

Serious and occasionally fatal hypersensitivity reactions (including anaphylactoid and severe cutaneous adverse reactions) have been reported in patients receiving therapy with beta-lactams. Before initiating therapy with sulbactam sodium/ampicillin sodium IM/IV, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, carbapenems or other beta-lactam agents. If an allergic reaction occurs, sulbactam sodium/ampicillin sodium IM/IV must be discontinued and appropriate alternative therapy instituted.

Serious anaphylactic reactions require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids and airway management, including intubation, should be administered as indicated.

Severe skin reactions, such as toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), dermatitis exfoliative, erythema multiforme, and acute generalized exanthematous pustulosis (AGEP) have been reported in patients on ampicillin/sulbactam therapy. If a severe skin reaction occurs, ampicillin/sulbactam should be discontinued and appropriate therapy should be initiated (see section 4.8 - **Undesirable Effects**).

As with any antibiotic preparation, constant observation for signs of overgrowth of non-susceptible organisms, including fungi, is essential. Should superinfection occur, the drug should be discontinued and/or appropriate therapy instituted.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including sulbactam sodium/ampicillin sodium, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

Drug induced liver injury such as cholestatic hepatitis and jaundice have been associated with the use of ampicillin/sulbactam. Patients should be advised to contact their doctor if signs and symptoms of hepatic disease develop (see section 4.8 - **Undesirable Effects**).

As with any potent systemic agent, it is advisable to check periodically for organ system dysfunction during extended therapy; this includes renal, hepatic and hematopoietic systems. This is particularly important in neonates, especially when premature, and other infants.

Since infectious mononucleosis is viral in origin, sulbactam sodium/ampicillin sodium IM/IV should not be used in its treatment. A high percentage of patients with mononucleosis who received ampicillin have developed a skin rash.

4.5 Interaction with Other Medicinal Products and Other Forms of Interaction

Allopurinol: The concurrent administration of allopurinol and ampicillin substantially increases the incidence of rashes in patients receiving both drugs as compared with patients receiving ampicillin alone.

Aminoglycosides: Mixing ampicillin with aminoglycosides *in vitro* has resulted in substantial mutual inactivation; if these groups of antibacterials are to be administered concurrently, they should be administered at separate sites at least 1 hour apart (see section 6.2 - **Incompatibilities**).

Anticoagulants: Parenteral penicillins can produce alterations in platelet aggregation and coagulation tests. These effects may be additive with anticoagulants.

Bacteriostatic drugs (chloramphenicol, erythromycin, sulfonamides and tetracyclines): Bacteriostatic drugs may interfere with the bactericidal effect of penicillins; it is best to avoid concurrent therapy.

Estrogen-containing oral contraceptives: There have been case reports of reduced oral contraceptive effectiveness in women taking ampicillin, resulting in unplanned pregnancy. Although the association is weak, patients should be given the option to use an alternate or additional method of contraception while taking ampicillin.

Methotrexate: Concurrent use with penicillins has resulted in decreased clearance of methotrexate and a corresponding increase in methotrexate toxicity. Patients should be closely monitored. Leucovorin dosages may need to be increased and administered for longer periods of time.

Probenecid: Probenecid decreases renal tubular secretion of ampicillin and sulbactam when used concurrently; this effect results in increased and prolonged serum concentrations, prolonged elimination half-life, and increased risk of toxicity.

Laboratory test interactions: False positive glycosuria may be observed in urinalysis using Benedict reagent, Fehling reagent, and Clinitest™. Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol,

estriol-glucuronide, conjugated estrone and estradiol has been noted. This effect may also occur with sulbactam sodium/ampicillin sodium IM/IV.

4.6 Fertility, Pregnancy and Lactation

Fertility

Animal reproduction studies have revealed no evidence of impaired fertility or harm to the fetus due to sulbactam and ampicillin.

Use During Pregnancy

Sulbactam and ampicillin cross the placental barrier. Safety for use during pregnancy has not been established. Therefore, sulbactam sodium/ampicillin sodium should be used during pregnancy only if the potential benefits outweigh the potential risks.

Use During Lactation

Low concentrations of sulbactam (~0.13 up to 2.8 mg/L) and ampicillin (~0.11 up to 3 mg/L) are excreted in the milk. The use of sulbactam sodium/ampicillin sodium by a nursing mother may lead to adverse effects such as diarrhea in the child. Sulbactam sodium/ampicillin sodium can be used during lactation if the potential benefits outweigh the potential risks.

4.7 Effects on Ability to Drive and Use Machines

None known.

4.8 Undesirable Effects

Adverse reactions associated with the use of ampicillin alone may be observed with sulbactam sodium/ampicillin sodium IM/IV.

All ADRs listed below are presented by MedDRA SOC. Within each frequency category, the ADRs are presented in the order of seriousness. Seriousness of the ADRs was determined by clinical importance.

Adverse Drug Reactions Table					
System Class	Organ	Common ≥1/100 to <1/10	Uncommon ≥1/1,000 to <1/100	Rare ≥1/10,000 to <1/1,000	Frequency Not Known (cannot be estimated from available data)
Infections	and infestations				Pseudomembranous colitis Candida infection
Blood and lymphatic system disorders		Anemia Thrombocytopenia Eosinophilia	Leukopenia Neutropenia		Hemolytic anemia Agranulocytosis Thrombocytopenic purpura
Immune system disorders					Anaphylactic shock Anaphylactic reaction Anaphylactoid shock

Adverse Drug Reactions Table				
System Organ Class	Common ≥1/100 to <1/10	Uncommon ≥1/1,000 to <1/100	Rare ≥1/10,000 to <1/1,000	Frequency Not Known (cannot be estimated from available data)
				Anaphylactoid reaction Kounis syndrome Hypersensitivity
Metabolism and nutrition disorders				Hypokalemia
Nervous system disorders		Headache		Convulsion Dizziness Somnolence Sedation
Vascular disorders	Phlebitis			
Respiratory, thoracic and mediastinal disorders				Dyspnea
Gastrointestinal disorders	Diarrhea	Vomiting	Abdominal pain Nausea Glossitis	Enterocolitis Melena Dyspepsia Stomatitis Tongue discoloration
Hepatobiliary disorders	Hyperbilirubinemia (see section 4.4 - Special Warnings and Precautions for Use)			Hepatitis cholestatic Cholestasis Hepatic function abnormal Jaundice (see section 4.4 - Special Warnings and Precautions for Use)
Skin and subcutaneous tissue disorders		Rash Pruritus		Stevens-Johnson syndrome Toxic epidermal necrolysis Drug reaction with eosinophilia and systemic symptoms Erythema multiforme Acute generalized exanthematous pustulosis Dermatitis exfoliative (see section 4.4 - Special Warnings)

Adverse Drug Reactions Table					
System Class	Organ	Common ≥1/100 to <1/10	Uncommon ≥1/1,000 to <1/100	Rare ≥1/10,000 to <1/1,000	Frequency Not Known (cannot be estimated from available data)
					and Precautions for Use) Linear IgA disease Angioedema Urticaria Dermatitis
Musculoskeletal and connective tissue disorders					Arthralgia
Renal and urinary disorders					Tubulointerstitial nephritis
General disorders and administration site conditions		Injection site pain	Fatigue Malaise		Injection site reaction
Investigations		Alanine aminotransferase increased Aspartate aminotransferase increased (see section 4.4 - Special Warnings and Precautions for Use)			

4.9 Overdose

Limited information is available on the acute toxicity of ampicillin sodium and sulbactam sodium in humans. Overdosage of the drug would be expected to produce manifestations that are principally extensions of the adverse reactions reported with the drug. The fact that high CSF concentrations of β -lactam antibiotics may cause neurologic effects, including seizures, should be considered. Because ampicillin and sulbactam are both removed from the circulation by hemodialysis, these procedures may enhance elimination of the drug from the body if overdosage occurs in patients with impaired renal function.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic Properties

Biochemical studies with cell-free bacterial systems have shown sulbactam to be an irreversible inhibitor of most important beta-lactamases that occur in penicillin-resistant organisms. While sulbactam's antibacterial activity is mainly limited to *Neisseriaceae*, the potential for sulbactam sodium in preventing the destruction of penicillins and cephalosporins by resistant organisms was confirmed in whole-organism studies using resistant strains, in which sulbactam sodium exhibited marked synergistic effects with penicillins and cephalosporins. Since sulbactam also binds to some penicillin-binding proteins, some sensitive strains are rendered more susceptible to the combination than to the β -lactam antibiotic alone.

The bactericidal component of the combination is ampicillin which, like benzyl penicillin, acts against sensitive organisms during the stage of active multiplication by the inhibition of biosynthesis of cell-wall mucopeptide.

Sulbactam sodium/ampicillin sodium IM/IV is effective against a wide range of Gram-positive and Gram-negative bacteria including: *Staphylococcus aureus* and *epidermidis* (including penicillin-resistant and some methicillin-resistant strains); *Streptococcus pneumoniae*, *Streptococcus faecalis* and other *Streptococcus* species; *Haemophilus influenzae* and *parainfluenzae* (both beta-lactamase positive and negative strains); *Branhamella catarrhalis*; anaerobes, including *Bacteroides fragilis* and related species; *Escherichia coli*, *Klebsiella* species, *Proteus* species (both indole-positive and indole-negative), *Morganella morganii*, *Citrobacter* species, *Enterobacter* species, *Neisseria meningitidis* and *Neisseria gonorrhoeae*.

5.2 Pharmacokinetic Properties

Sulbactam sodium/ampicillin sodium IM/IV diffuses readily into most body tissues and fluids in the human. Penetration into brain and spinal fluid is low except when meninges are inflamed. High concentrations of sulbactam and ampicillin are achieved in the blood following intravenous or intramuscular administration and both components have a half-life of approximately 1 hour. Most of the sulbactam sodium/ampicillin sodium IM/IV is excreted unchanged in the urine.

5.3 Preclinical Safety Data

While reversible glycogenosis was observed in laboratory animals, this phenomenon was dose- and time-dependent and is not expected to develop at the therapeutic doses and corresponding plasma levels attained during the relatively short periods of combined ampicillin/sulbactam therapy in humans.

Long-term studies in animals have not been performed to evaluate the carcinogenic potential. The individual components, ampicillin and sulbactam, tested negative for mutagenicity.

Reproduction studies have been performed in mice and rats with sultamicillin, an oral prodrug that hydrolyzes *in vivo* to release ampicillin and sulbactam, at doses in excess of the human dose and have revealed no evidence of impaired fertility or harm to the fetus.

6. PHARMACEUTICAL PARTICULARS

6.1 List of Excipients

None.

6.2 Incompatibilities

Sulbactam sodium/ampicillin sodium IM/IV and aminoglycosides should be reconstituted and administered separately, due to the *in vitro* inactivation of aminoglycosides by any of the aminopenicillins.

6.3 Shelf-Life

Observe "Expiry date" (month/year) imprinted on outer carton.

6.4 Special Precautions for Storage

Store below 30°C.

6.5 Nature and Contents of Container

Available in single vial packing of 0.750 g, 1.500 g and 3.000 g.

6.6 Special Precautions for Disposal and Other Handling

Sulbactam sodium is compatible with most intravenous solutions, but ampicillin sodium and hence sulbactam sodium/ampicillin sodium IM/IV is less stable in solutions containing dextrose or other carbohydrates, and should not be mixed with blood products or protein hydrolysates. Ampicillin and hence sulbactam sodium/ampicillin sodium IM/IV is incompatible with aminoglycosides and should not be physically mixed in the same container (see section 4.2 – **Posology and Method of Administration**). The concentrated solution for intramuscular administration should be used within 1 hour of reconstitution. Time periods for use with different diluents for intravenous infusion are as follows:

Diluent	Concentration	Use Periods (In Hours)	
		25°C	4°C
Sterile Water for Injection	up to 45 mg/ml	8	
	45 mg/ml		48
	up to 30 mg/ml		72
Isotonic Sodium Chloride	up to 45 mg/ml	8	
	45 mg/ml		48
	up to 30 mg/ml		72
M/6 Sodium Lactate Solution	up to 45 mg/ml	8	
	up to 45 mg/ml		8
5% Dextrose in Water	15 to 30 mg/ml	2	
	up to 3 mg/ml	4	
	up to 30 mg/ml		4
5% Dextrose in 0.45% NaCl	up to 3 mg/ml	4	
	up to 15 mg/ml		4
10% Invert Sugar in Water	up to 3 mg/ml	4	
	up to 30 mg/ml		3
Lactated Ringer's Solution	up to 45 mg/ml	8	
	up to 45 mg/ml		24

7. MANUFACTURER

Haupt Pharma Latina S.r.l.
Latina, Italy

Under the authority of
Pfizer Inc., New York,
NY, USA

UNASYN IMIV-0225
Date of last revision: February 2025